Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?
Elizabeth Dravis was a medical field professional, a PhD student at UTHealth School of Public Health in Houston, an avid runner, and mother of two when she star